Podcast: Servier’s Head of Business Development on M&A, Manufacturing, and AI-Driven Growth

In the wake of multibillion-dollar acquisitions and AI-driven partnerships, Servier’s head of business development details how the French pharmaceutical leader is positioning itself for the future against a shifting geopolitical backdrop.

In 2026, Servier finalized a $2.5 billion purchase of oncology firm Day One Biopharmaceuticals and secured Edgewise Therapeutics’ muscular dystrophy unit for approximately $2.65 billion, building on significant AI collaborations with InSilico Medicine and Iktos. In the most recent podcast episode, Pharmaceutical Technology journalist Frankie Fattorini converses with business development chief Frederic Scaerou about how these transactions are redefining Servier as the French multinational adapts to evolving global industry dynamics.

Source link